- 0207 299 0388
- Weekday Hours: 10AM - 5PM
*In some cases, if the doctor requires more information, you may be asked to answer follow-up questions or attend a 1-to-1 virtual consultation before a prescription is approved
*In some cases, if the doctor requires more information, you may be asked to answer follow-up questions or attend a 1-to-1 virtual consultation before a prescription is approved
Women who are overweight or obese have larger amounts of the hormone leptin, which is made in
adipose tissue. This may throw off the hormone balance and lower fertility rates. According to studies,
12% to 15% of couples who struggle with infertility that engage in unprotected sex after a year are still
unable to conceive, and 10% of couples who do not conceive after two years still do not have a live birth.
Women who are overweight or obese have larger amounts of the hormone leptin, which is made in adipose tissue. This may throw off the hormone balance and lower fertility rates. According to studies, 12% to 15% of couples who struggle with infertility that engage in unprotected sex after a year are still unable to conceive, and 10% of couples who do not conceive after two years still do not have a live birth.
Infertility and weight gain are linked with weight being a factor
for infertility. Mounjaro aids in weight loss and therefore would
help improve pregnancy outcomes. After the doctor reviews the
patient in a consultation, it will determine if the patient is
suitable to use the medication. The patient would start on the
starter dose of 2.5mg if approved for Mounjaro.
Infertility and weight gain are linked with weight being a factor for infertility. Mounjaro aids in weight loss and therefore would help improve pregnancy outcomes. After the doctor reviews the patient in a consultation, it will determine if the patient is suitable to use the medication. The patient would start on the starter dose of 2.5mg if approved for Mounjaro.
Mounjaro works by mimicking the effects of two natural hormones, glucose-dependent insulinotropic
polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). These hormones help to control blood sugar levels by
increasing insulin secretion, slowing gastric emptying, and suppressing glucagon secretion.
Increasing insulin secretion: Mounjaro stimulates the release of insulin from the pancreas, which helps to
lower blood sugar levels.
Slowing gastric emptying: Mounjaro slows down the movement of food from the stomach into the small
intestine, which helps you feel full for longer and eat less.
Suppressing glucagon secretion: Mounjaro reduces the release of glucagon from the pancreas, which helps to prevent the liver from releasing too much sugar into the bloodstream.
Mounjaro works by mimicking the effects of two natural hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). These hormones help to control blood sugar levels by increasing insulin secretion, slowing gastric emptying, and suppressing glucagon secretion.
Increasing insulin secretion:
Mounjaro stimulates the release of insulin from the pancreas, which helps to lower blood sugar levels.
Slowing gastric emptying:
Mounjaro slows down the movement of food from the stomach into the small
intestine, which helps you feel full for longer and eat less.
Suppressing glucagon secretion:
Mounjaro reduces the release of glucagon from the pancreas, which helps to prevent the liver from releasing too much sugar into the bloodstream.
Mounjaro, a medication originally approved for type 2 diabetes, has shown promise in addressing
some symptoms of Polycystic Ovary Syndrome (PCOS), particularly in areas that can indirectly
impact fertility. PCOS often involves insulin resistance and obesity, which can contribute to irregular
menstrual cycles and infertility. By improving insulin sensitivity and promoting weight loss,
Mounjaro may help alleviate some of these issues, thereby improving fertility outcomes in women
with PCOS.
Mounjaro, a medication originally approved for type 2 diabetes, has shown promise in addressing some symptoms of Polycystic Ovary Syndrome (PCOS), particularly in areas that can indirectly impact fertility. PCOS often involves insulin resistance and obesity, which can contribute to irregular menstrual cycles and infertility. By improving insulin sensitivity and promoting weight loss, Mounjaro may help alleviate some of these issues, thereby improving fertility outcomes in women with PCOS.
Before recommending Mounjaro for weight management, medical professionals will evaluate a number of aspects, including general health and BMI. If the patient meets the eligibility requirements and the medicine is deemed appropriate for managing their weight, they can be prescribed Mounjaro. There maybe a few factors preventing the prescribing of Mounjaro such as Thyroid cancer or any medical conditions which could be a health risk.
Before recommending Mounjaro for weight management, medical professionals will evaluate a number of aspects, including general health and BMI. If the patient meets the eligibility requirements and the medicine is deemed appropriate for managing their weight, they can be prescribed Mounjaro. There maybe a few factors preventing the prescribing of Mounjaro such as Thyroid cancer or any medical conditions which could be a health risk.
Read our articles on Mounjaro and Wegovy if you would like to learn more about the benefits, the research and case studies.
Weight loss induced by Mounjaro can improve fertility, especially in women with obesity or polycystic ovary syndrome (PCOS), where insulin resistance plays a key role. By improving insulin sensitivity and reducing androgen levels, ovulation can resume. However, there’s no evidence that tirzepatide itself directly enhances or impairs fertility.
There is no evidence that Mounjaro causes infertility. In fact, by correcting metabolic dysfunctions such as insulin resistance it may restore reproductive hormone balance. However, rapid weight loss or inadequate nutrition during therapy could temporarily affect menstrual cycles.
It’s not recommended to use Mounjaro while trying to conceive. There are no sufficient human studies on tirzepatide’s safety in pregnancy. Animal studies have shown potential risks to foetal development, so discontinuation is advised before conception.
Because tirzepatide has a long half-life (about 5 days), most guidelines suggest stopping the medication at least 1–2 months before attempting conception to allow the drug to fully clear from the body.
Yes, indirectly. In PCOS, insulin resistance leads to hyperandrogenism and anovulation. Mounjaro helps by lowering insulin and androgen levels, promoting ovulation and potentially increasing natural fertility, similar to how GLP-1 receptor agonists like liraglutide have shown benefits in PCOS women.
There are no known long-term fertility risks reported in humans. Most observed hormonal or reproductive benefits are tied to improvements in metabolic health rather than the drug itself.
Yes, but it can be taken only after the breastfeeding period ends and under medical guidance. Mounjaro can safely be resumed for weight and glucose management in the postpartum period, provided pregnancy and lactation are complete.
Yes, in men with obesity or insulin resistance, Mounjaro can help raise testosterone levels and improve sperm quality through weight loss and better metabolic control.
No, it is approved for weight management and diabetes, not infertility and however, improving weight and insulin sensitivity often enhances natural fertility in insulin-resistant women.
It is best to limit or avoid alcohol, since both Mounjaro and alcohol can lower blood sugar unpredictably, and alcohol can interfere with fertility and foetal development.
Book an Appointment Today
Sign-up using your e-mail to regularly receive useful
& interesting weight loss information!
By clicking signup you agree to our Privacy Policy and Terms of Use
All consultations and prescriptions are carried out by GMC registered medical practitioners.
All dispensing and shipping of medicines are completed by a UK licensed, GPhC registered Pharmacy no: 9011284.
CloudRx is our partner pharmacy and prescribing service.
*Disclaimer: Results may vary from person to person depending on individual engagement and commitment to the programme.
The content of this website is provided for general informational purposes only and is not intended as, nor should it be considered a substitute for, professional medical advice. Do not use the information on this website for diagnosing or treating any medical or health related condition. If you have or suspect you have a medical problem, promptly contact your healthcare provider.
© 2025 The London Obesity Clinic
